2015
DOI: 10.1002/14651858.cd005614.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Chondroitin for osteoarthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

7
85
1
31

Year Published

2015
2015
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 180 publications
(133 citation statements)
references
References 91 publications
(438 reference statements)
7
85
1
31
Order By: Relevance
“…31,43,61) High-dose CS therapy was tolerable in the present study, and there was no increased drop-off rate compared to low-dose therapy. Also consistent with previous studies, we showed that there were no serious adverse effects attributable to CS and that tolerability was good.…”
supporting
confidence: 46%
See 2 more Smart Citations
“…31,43,61) High-dose CS therapy was tolerable in the present study, and there was no increased drop-off rate compared to low-dose therapy. Also consistent with previous studies, we showed that there were no serious adverse effects attributable to CS and that tolerability was good.…”
supporting
confidence: 46%
“…[4][5][6][7][28][29][30] Singh et al recently conducted a review of randomized trials of OA interventions in the Cochrane Database of Systemic Reviews and concluded that CS may improve pain, that it probably improves QOL, and that it probably slows down narrowing of the joint space in patients with knee OA. 31) However, there have also been reports showing no effects of CS on pain or cartilage structure. 6,32,33) It is possible that differences in disease severity among patients caused the discrepancy in the effect of CS on OA symptoms among studies.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…It has been suggested to restore the extracellular matrix of cartilage, reducing degradation in OA, and provide sulphur-containing amino acids that are essential for the cartilage extra-cellular matrix, which may be deficient from regular diets [24,25]. A systematic review of chondroitin found that chondroitin had small to moderate effects on pain and physical function in patients with OA, which were clinically significant [26]. It also noted the lower risk of adverse events in patients taking chondroitin supplementation.…”
Section: Chondroitinmentioning
confidence: 99%
“…Prema rezultatima Kohranove analize randomizovanih kliničkih studija, kratkotrajna primena hondroitin-sulfata (< 6 meseci), pojedinačno ili u kombinaciji sa glukozaminom, bezbedna je i ima blagi do umereno izraženi efekat na simptome bola i suženje zglobnog prostora kod OA kolena. Međutim, neophodan je veći broj kvalitetno dizajniranih kliničkih ispitivanja kako bi se utvrdio klinički značaj suplementacije hondroitin-sulfatom (52). U pogledu strukturno-modifikujućih efekata, nedavna studija Pelletier i sar., pokazala je da je primena hondroitin-sulfata (1200 mg/dan) tokom 24 meseca, efikasnija u odnosu na celokoksib u pogledu usporavanja gubitka artikularne hrskavice kolena, praćeno kvantitativnom magnetnom rezonancom (qMRI) (53).…”
Section: Hondroitin-sulfatunclassified